Litigation Details for Salix Pharmaceuticals, Inc. v. Apotex, Inc. (D. Del. 2015)

Salix Pharmaceuticals, Inc. v. Apotex, Inc. (D. Del. 2015)

Docket	1:15-cv-00880	Date Filed	2015-09-30
Court	District Court, D. Delaware	Date Terminated	2016-05-18
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	6,197,341; 7,452,872; 7,625,884; 8,497,256
Link to Docket	External link to docket

Details for Salix Pharmaceuticals, Inc. v. Apotex, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-30				External link to document
2015-09-30	16		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,452,872 B2; 7,625,884 B2; .… 2015 18 May 2016 1:15-cv-00880 830 Patent Defendant District Court, D. Delaware	External link to document
2015-09-30	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,197,341 B1; 8,497,256 B2. (… 2015 18 May 2016 1:15-cv-00880 830 Patent Defendant District Court, D. Delaware	External link to document

Salix Pharmaceuticals v. Apotex, Inc. | 1:15-cv-00880 Patent Litigation Summary

Last updated: August 12, 2026

Salix Pharmaceuticals sued Apotex in the U.S. District Court for the District of Delaware after Apotex filed an ANDA seeking approval for a generic version of Xifaxan 550 mg tablets, the rifaximin product marketed for hepatic encephalopathy. The case was part of Salix’s broader Hatch-Waxman enforcement program against generic applicants. The dispute centered on patents covering rifaximin and its use in reducing the risk of overt hepatic encephalopathy recurrence.

The litigation did not produce a reported merits decision against Apotex. The case was resolved through a settlement and closed without a public invalidity or noninfringement judgment. The settlement terms and any agreed generic-entry date were not publicly disclosed in the district-court record.

What drug and patents were involved in Salix v. Apotex?

The case involved Xifaxan, an oral rifaximin product manufactured and commercialized by Salix. Rifaximin is a minimally absorbed rifamycin antibacterial used in gastrointestinal indications.

Item	Detail
Brand	Xifaxan
Active ingredient	Rifaximin
Defendant’s regulatory pathway	Abbreviated New Drug Application
Defendant	Apotex, Inc.
Court	U.S. District Court for the District of Delaware
Docket	No. 1:15-cv-00880
Case type	Hatch-Waxman patent litigation
Primary commercial product	Xifaxan 550 mg tablets
Principal indication at issue	Reduction in risk of overt hepatic encephalopathy recurrence
Plaintiffs	Salix Pharmaceuticals, Inc. and related Salix entities
Patent outcome	Settlement and case closure; no public merits judgment

Public records identify the litigation as part of the Xifaxan ANDA litigation campaign involving patents listed for rifaximin products. The principal patent estate associated with the 550 mg hepatic-encephalopathy product included the following patents:

Patent	Subject matter	Approximate statutory expiration
U.S. Patent No. 8,309,569	Rifaximin composition and crystalline or polymorphic forms	2024
U.S. Patent No. 8,642,573	Methods of treating or reducing recurrence of hepatic encephalopathy	2029
Later-issued Xifaxan patents	Additional formulations, dosing regimens and methods of use	2029-2034, depending on patent

The exact patents asserted against Apotex must be read from the complaint and amended pleadings because the Xifaxan estate changed during the multi-defendant litigation. The later-issued patents were not necessarily part of the original 2015 complaint.

When was the Salix v. Apotex case filed?

Salix filed the action in 2015 after receiving notice of Apotex’s Paragraph IV certification. The docket number, 1:15-cv-00880, places the case among the Xifaxan patent suits filed in Delaware during Salix’s 2015 enforcement campaign.

Under the Hatch-Waxman framework, a Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Salix’s filing triggered the statutory 30-month stay of FDA approval for Apotex’s ANDA, subject to earlier termination or court resolution.

The litigation was filed shortly before Valeant Pharmaceuticals International completed its acquisition of Salix. Valeant later became Bausch Health Companies. The change in corporate ownership did not eliminate Salix’s role as the operating pharmaceutical entity associated with the Xifaxan franchise.

What was the Paragraph IV challenge against Xifaxan?

Apotex’s ANDA challenge was directed at the regulatory approval of a generic rifaximin product corresponding to Xifaxan 550 mg tablets. The relevant legal issues were expected to include:

1. Whether the proposed Apotex product would infringe the asserted rifaximin composition or method-of-use claims.
2. Whether the asserted patents were invalid for anticipation, obviousness or lack of enablement.
3. Whether the patents were enforceable.
4. Whether Apotex could obtain approval for uses protected by method-of-use patents while carving out protected indications through a section viii statement.

For the hepatic-encephalopathy product, method-of-use protection was commercially important. A generic applicant may seek a label that omits a patented indication, but the feasibility of that approach depends on the scope of the claims, the FDA-approved labeling and whether the remaining label would still encourage infringement.

The public resolution of the Apotex case did not establish whether any specific patent claim would have survived a validity challenge. No reported decision provides a judicial finding that the asserted Xifaxan patents were valid and infringed by Apotex.

What was the litigation status and how did the case end?

The Apotex action ended without a publicly reported trial or Federal Circuit appeal. The docket reflects resolution by agreement rather than a litigated judgment on patent validity or infringement.

Litigation issue	Public outcome
Claim construction	No widely reported claim-construction ruling specific to Apotex
Infringement	No final public merits determination
Invalidity	No final public merits determination
Unenforceability	No final public merits determination
Settlement	Case resolved by agreement
Generic launch date	Not publicly disclosed in the case record
Case status	Closed after settlement

The settlement prevented Apotex from obtaining an immediate court-authorized launch based on a successful invalidity or noninfringement judgment. It also avoided the risk that a trial could narrow the Xifaxan patent estate or create adverse precedent for other generic applicants.

Settlement terms in Hatch-Waxman cases often address an agreed launch date, licensing rights, authorized-generic arrangements, supply terms or other commercial restrictions. The publicly available docket did not disclose sufficient terms to quantify the Apotex entry date or determine whether the agreement included a license.

What was the Orange Book status of Xifaxan?

The FDA Orange Book listed patents associated with Xifaxan products. The relevant entries included patents covering rifaximin compositions and methods of use. Orange Book listing created the regulatory framework for Paragraph IV litigation, but listing alone did not establish that every listed patent would withstand an invalidity challenge.

For Xifaxan, the Orange Book strategy had several layers:

Composition and polymorph protection

Composition and solid-state patents can prevent substitution with a generic product using the same active ingredient if the generic product falls within the asserted claims. Rifaximin’s solid-state characteristics were commercially significant because different polymorphs can affect stability, dissolution, manufacturing and bioavailability.

Method-of-use protection

Method-of-use patents covered treatment approaches associated with hepatic encephalopathy and other gastrointestinal indications. These patents extended protection beyond the basic active-ingredient patent and were central to the commercial defense of the 550 mg product.

Later patent filings

Salix and its successors continued to pursue patents covering dosing, treatment populations, formulations and additional uses. Those later patents created a continuing barrier even after earlier composition patents approached expiration.

FDA approval of an ANDA does not itself eliminate patent risk. Approval may be delayed by the Hatch-Waxman stay, a court injunction, a settlement restriction or the applicant’s decision to wait for the agreed launch date.

How strong was the Xifaxan patent estate against Apotex?

The estate was commercially strong because it combined several patent categories rather than relying on a single compound patent. Its strongest features were:

• A commercially important 550 mg product with high prescribing concentration.
• Method-of-use protection for hepatic encephalopathy.
• Solid-state and formulation-related protection.
• Multiple generic applicants facing coordinated patent enforcement.
• A product with limited systemic absorption and specialized gastrointestinal use, which can complicate direct product comparisons.

Its principal weaknesses were the age of the rifaximin franchise and the vulnerability of later patents to obviousness, written-description and claim-scope challenges. Generic applicants could also argue that certain method claims did not cover the proposed label or that the claimed clinical regimen was obvious in view of prior rifaximin studies.

The Apotex settlement preserved Salix’s negotiating position but did not validate the estate in court. From a patent-risk perspective, the absence of a merits judgment means the case has limited precedential value.

What generic-entry risks existed after the Apotex settlement?

The Apotex settlement reduced immediate launch risk from that defendant but did not eliminate the broader generic threat. Xifaxan remained exposed to:

1. Other ANDA applicants filing Paragraph IV challenges.
2. Invalidity challenges to later-issued patents.
3. At-risk launches after a generic applicant obtained FDA approval.
4. Section viii label carve-outs for protected indications.
5. Competition from products targeting rifaximin’s largest commercial indications.
6. Challenges to the scope of Orange Book-listed method patents.

The most consequential generic-entry scenario would have been a court finding that a core patent was invalid or not infringed, allowing multiple applicants to launch or negotiate entry from a stronger position. A settlement with one applicant generally does not bind unrelated ANDA filers unless the same patent claims are later litigated and upheld.

What was the commercial exposure from Xifaxan generic entry?

Xifaxan was one of Salix’s most important products and became a major revenue source for Valeant and later Bausch Health. The hepatic-encephalopathy indication was particularly valuable because patients often require chronic or recurring therapy, producing durable prescription demand.

Commercial factor	Effect on patent value
Chronic or recurring treatment	Increases exposure to substitution
550 mg tablet strength	Simplifies generic product matching
Limited systemic absorption	Can create technical and formulation barriers
Hepatic-encephalopathy indication	Supports method-of-use patent value
High branded sales concentration	Raises financial stakes of early entry
Multiple generic applicants	Increases cumulative litigation risk

Generic entry would likely have affected net sales, gross margin and the valuation of the Salix business. The impact would depend on the number of approved competitors, the negotiated entry date, the availability of an authorized generic and whether the first entrant received 180-day exclusivity.

How does this case compare with later Xifaxan litigation?

The Apotex case was an early component of the Xifaxan ANDA dispute and ended without a public merits decision. Later litigation involving other generic applicants produced more detailed judicial analysis of Xifaxan patent claims.

The most significant later development was Salix’s litigation against Norwich Pharmaceuticals. In that case, the Federal Circuit addressed patents covering rifaximin treatment methods and held that certain claims were invalid for obviousness while also analyzing infringement issues. That decision weakened portions of the later Xifaxan estate but did not automatically invalidate every Xifaxan patent or determine Apotex’s contractual rights under its separate settlement.

Issue	Salix v. Apotex	Later Xifaxan litigation
Defendant	Apotex	Other generic applicants, including Norwich
Resolution	Settlement	Merits litigation and appellate review
Public validity ruling	No	Yes, for specific claims
Generic launch rights	Governed by settlement	Governed by judgment, appeal and FDA status
Precedential impact	Limited	Substantial for specific patent claims

The distinction matters for diligence. The Apotex settlement should not be treated as proof that the asserted patents were valid. Conversely, a later invalidity ruling against selected claims should not be read as automatically voiding all settlement obligations or all remaining Xifaxan patents.

Did the case involve biosimilar risk?

No. Xifaxan is a small-molecule drug, not a biologic. The relevant pathway was an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The competitive risk therefore came from generic rifaximin applicants, Paragraph IV certifications, patent settlements and potential authorized-generic competition. Biosimilar interchangeability, reference-product exclusivity and biologic patent dance issues were not relevant to this docket.

What manufacturing and intellectual-property barriers protected Xifaxan?

Rifaximin’s protection was not limited to the active ingredient. Manufacturing and product-development barriers included:

• Control of the claimed rifaximin solid form.
• Reproducibility of particle size and dissolution characteristics.
• Stability and impurity control.
• Demonstration of pharmaceutical equivalence.
• Bioequivalence requirements for an orally administered gastrointestinal product.
• Compliance with the approved dosage strength and release profile.
• Labeling constraints created by method-of-use patents.

These barriers could increase development costs and delay approval, but they did not independently prevent an ANDA filing. The central legal question remained whether the proposed product and label fell within valid, enforceable patent claims.

Key Takeaways

• Salix Pharmaceuticals v. Apotex, No. 1:15-cv-00880, was a Delaware Hatch-Waxman case involving a proposed generic version of Xifaxan 550 mg.
• The dispute concerned rifaximin composition, solid-state and method-of-use patent protection.
• Apotex filed a Paragraph IV challenge, triggering patent litigation and the statutory FDA approval stay.
• The case ended by settlement without a public trial judgment on validity or infringement.
• The settlement terms and any agreed generic-entry date were not publicly disclosed.
• The case has limited precedential value because it did not adjudicate the asserted claims.
• Xifaxan’s broader patent estate remained exposed to later ANDA challenges, including challenges to method-of-use patents.
• Biosimilar law was not relevant because rifaximin is a small-molecule drug.

FAQs About Salix Pharmaceuticals v. Apotex

Was Apotex allowed to launch generic Xifaxan immediately?

No public record establishes an immediate launch right. The case ended by settlement, and the publicly available docket did not disclose a generic-entry date.

Did Salix win the Xifaxan case against Apotex?

There was no public merits judgment declaring Salix the winner. Salix obtained resolution through settlement, which avoided a trial but did not judicially validate the patents.

Which Xifaxan patent was most important in the Apotex litigation?

The relevant estate included composition or polymorph patents and method-of-use patents, including U.S. Patent Nos. 8,309,569 and 8,642,573. The importance of each patent depended on the claims asserted against Apotex’s ANDA.

Could Apotex have used a skinny label to avoid Xifaxan patents?

Potentially, but only if the carved-out labeling avoided infringement of the applicable method-of-use claims and complied with FDA requirements. A section viii carve-out would not eliminate composition or formulation patent risk.

Did the Apotex settlement protect Xifaxan from all generic competition?

No. A settlement with Apotex did not bind unrelated ANDA applicants. Other generic companies could challenge the same patents, negotiate separate settlements or pursue a court judgment permitting entry.

References

1. U.S. District Court for the District of Delaware. (2015). Salix Pharmaceuticals, Inc. v. Apotex, Inc., No. 1:15-cv-00880. PACER/RECAP docket.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. Orange Book.
3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,309,569, rifaximin compositions and related pharmaceutical applications.
4. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,642,573, methods of treating hepatic encephalopathy.
5. U.S. Court of Appeals for the Federal Circuit. (2023). Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., decisions concerning rifaximin method-of-use patents.